Press Room

Duchesnay USA is excited to announce the launch of its newly redesigned Diclegis® (doxylamine succinate and pyridoxine hydrochloride) website

Rosemont, PA. – March 1, 2017 – Duchesnay USA is proud to announce the launch of the newly redesigned Diclegis® website. The new site offers complete functionality on any mobile device, ensuring that both healthcare providers and patients can easily access valuable information and resources anytime, anywhere.

In keeping with Duchesnay USA’s unwavering commitment to women’s health, the new Diclegis® website also offers:

Important information for healthcare providers

The new site contains the most up-to-date information about how healthcare providers can help their pregnant patients manage their morning sickness symptoms when diet and lifestyle changes do not provide adequate relief.

PUQE score assessment

The site contains the PUQE (Pregnancy Unique Quantification of Emesis) survey, a short and simple symptom tracking questionnaire for patients to help healthcare providers assess the severity of symptoms and determine the appropriate course of treatment.

Clinical trial information

The site contains detailed information regarding the clinical trials used to demonstrate Diclegis’ safety and efficacy.

Patient savings information

The site includes important information about our Copay savings card and our Patient Assistance Program to help make Diclegis® affordable and accessible for as many patients who need it as possible.

Patient resources

The site also contains important information and carefully selected resources for expectant mothers, as well as links to additional sources.

Professional and patient testimonial videos

The site contains video testimonials from healthcare professionals and patients regarding their experiences prescribing and using the product.

User-friendly, visually appealing layout

Duchesnay USA has also given the website a fresh, modern look that is more visually appealing and consistent with our recently updated marketing materials.

Please visit now!


Tell us what you think!

We hope you enjoy our new site and welcome your feedback. If you have questions, comments or suggestions, please send them to This email address is being protected from spambots. You need JavaScript enabled to view it.


Indication and Important Safety Information


Diclegis is a prescription medicine used to treat nausea and vomiting of pregnancy in women who have not improved with change in diet or other non-medicine treatments.

Limitations of Use

Diclegis has not been studied in women with hyperemesis gravidarum.

Important Safety Information

Do not take Diclegis if you are allergic to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any of the ingredients in Diclegis. You should also not take Diclegis in combination with medicines called monoamine oxidase inhibitors (MAOIs), as these medicines can intensify and prolong the adverse central nervous system (CNS) effects of Diclegis.

The most common side effect of Diclegis is drowsiness. Do not drive, operate heavy machinery, or other activities that need your full attention unless your healthcare provider says that you may do so.

Do not drink alcohol, or take other CNS depressants such as cough and cold medicines, certain pain medicines, and medicines that help you sleep while you take Diclegis. Severe drowsiness can happen or become worse causing falls or accidents.

Diclegis should be used with caution in women who have certain medical conditions, such as asthma, or eye, stomach or bladder problems. Tell your healthcare provider about all of your medical conditions so he/she can assess if Diclegis is right for you.

It is not known if Diclegis is safe and effective in children under 18 years of age. Keep Diclegis and all medicines out of the reach of children.

Diclegis is a delayed-release formulation, so signs of overdose may not appear right away. If you take too much Diclegis (overdose), you may have the following symptoms: restlessness, dry mouth, the pupils of your eyes become larger (dilated), sleepiness, dizziness, confusion, fast heart rate, seizures, muscle pain or weakness, and sudden and severe kidney problems. If you have these symptoms and they are severe, they may lead to death. Stop taking Diclegis, call your healthcare provider or go to the nearest hospital emergency room right away. For more information about overdose treatment, call your poison control center at 1-800-222-1222.

Diclegis is intended for use in pregnant women.

Tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. Diclegis can pass into your breast milk and may harm your baby. You should not breastfeed while using Diclegis.

Duchesnay USA encourages you to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.
For additional important safety information, please see full Prescribing and Patient Information. This information is not intended to replace discussions with your healthcare provider.

About Duchesnay USA

Duchesnay is a specialty pharmaceutical company with a long-standing commitment to women’s health. In addition to filling the void in terms of scientific research, education and information and developing pharmacological solutions that are safe for use during pregnancy and breastfeeding, Duchesnay is equally committed to ensuring women’s health and improving their quality of life at every stage.

Thus, Duchesnay is broadening its portfolio of products to offer safe and effective therapeutic options that meet the health and quality of life needs of women and their family members at different stages of their lives.

For more information about Duchesnay USA, please visit